HealthdirectFree Australian health advice you can count on.

• Women of childbearing age should take effective contraceptive measures during the treatment with binimetinib and should continue that for at least 30 days after the last dose of binimetinib. • Breastfeeding mothers should not breastfeed their children during binimetinib treatment and for at least three days after the last dose. • Patients must confirm for the presence of BRAF V600E or V600K gene mutation with an FDA approved test before starting treatment with binimetinib. • A MUGA (Multigated Acquisition) scan to find heart’s pumping function or an ECG should be taken before starting treatment with binimetinib, a month after treatment and continued every two or three months during the treatment. • Blood clots can occur deep in the blood vessels while treating with binimetinib.‍‍‍‍‍‍​​​‍​​​​​​ Some clots can travel to the lungs resulting in blockade of blood supply to the lungs (i.e., Pulmonary embolism). In such situations, the dose of binimetinib can be reduced or treatment can be discontinued. • Various eye disorders including new or worsening of visual disturbances can occur with binimetinib treatment; therefore patients should be advised to meet an eye specialist and to check their eye function at regular intervals. • Airway disease including pneumonitis, heart problems, liver toxicity and severe muscle weakness may occur during binimetinib treatment. So, patients must be monitored for any signs and symptoms and should be treated accordingly. • Bleeding events can occur during treatment with binimetinib and encorafenib combination. The most common place of bleeding is in stomach and worsening of bleeding in hemorrhoids or piles which require treatment modification.